InspireMD (NSPR) Research & Development (2010 - 2025)

InspireMD has reported Research & Development for 16 years, with the latest figure at $3.5 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 5.9% year-over-year to $3.5 million; the trailing twelve-month figure through Dec 2025 stood at $15.0 million (up 10.04% YoY), and the FY2025 full-year result was $15.0 million, up 10.04% from the prior year.
• Research & Development for Q4 2025 stood at $3.5 million, down from $3.6 million in the prior quarter.
• The five-year high for Research & Development was $4.1 million in Q1 2025, with the low at $839000.0 in Q1 2021.
• Historically, Research & Development has averaged $2.5 million across 5 years, with a median of $2.1 million in 2022.
• Annual changes were most pronounced in 2021 — Research & Development surged 190.54% — and 2025, when it slipped 7.15%.
• InspireMD's Research & Development stood at $1.5 million in 2021, then soared by 31.23% to $2.0 million in 2022, then advanced by 1.09% to $2.0 million in 2023, then surged by 81.47% to $3.7 million in 2024, then decreased by 5.9% to $3.5 million in 2025.
• The last three Research & Development figures came in at $3.5 million (Q4 2025), $3.6 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.